Who are norelgestromin + ethinyl estradiol; triphasil.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Phase 3 NOMAC-E2 "Batch A", Estradiol + Progesterone, placebo + ethinylestradiol/levonorgestrel, ethinyl estradiol/etonogestrel vaginal ring, Ethinyl Estradiol + Cyproterone acetate, Subcutaneous depot medroxyprogesterone acetate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/norelgestromin-ethinyl-estradiol-triphasil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

norelgestromin + ethinyl estradiol; triphasil. — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

norelgestromin + ethinyl estradiol; triphasil. (norelgestromin + ethinyl estradiol; triphasil.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: contraceptive. Area: Women's Health.

phase 3 contraceptive Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

norelgestromin + ethinyl estradiol; triphasil. (norelgestromin + ethinyl estradiol; triphasil.) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Norelgestromin and ethinyl estradiol work together to prevent ovulation and thicken cervical mucus to prevent sperm from reaching the egg.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
norelgestromin + ethinyl estradiol; triphasil. TARGET	norelgestromin + ethinyl estradiol; triphasil.	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	contraceptive
Phase 3 NOMAC-E2 "Batch A"	Phase 3 NOMAC-E2 "Batch A"	Organon and Co	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Estradiol + Progesterone	Estradiol + Progesterone	Productos Científicos S. A. de C. V.	marketed	Hormone replacement therapy / Oral contraceptive	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR)
placebo + ethinylestradiol/levonorgestrel	placebo + ethinylestradiol/levonorgestrel	HRA Pharma	marketed	Combined oral contraceptive	Estrogen receptor and progesterone receptor
ethinyl estradiol/etonogestrel vaginal ring	ethinyl estradiol/etonogestrel vaginal ring	University of Pittsburgh	marketed	Combined hormonal contraceptive	Estrogen receptor and progesterone receptor
Ethinyl Estradiol + Cyproterone acetate	Ethinyl Estradiol + Cyproterone acetate	Fundação Educacional Serra dos Órgãos	marketed	Combined oral contraceptive with anti-androgenic activity	Androgen receptor (cyproterone acetate); estrogen receptor (ethinyl estradiol); gonadotropin suppression
Subcutaneous depot medroxyprogesterone acetate	Subcutaneous depot medroxyprogesterone acetate	Planned Parenthood Federation of America	marketed	Progestin contraceptive	Progesterone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (contraceptive class)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2 drugs in this class
Ospedale Policlinico San Martino · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). norelgestromin + ethinyl estradiol; triphasil. — Competitive Intelligence Brief. https://druglandscape.com/ci/norelgestromin-ethinyl-estradiol-triphasil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab